ATE486070T1 - Piperidinylaminopyridazine und ihre verwendung als schnelldissoziierende antagonisten des dopamin-2-rezeptors - Google Patents

Piperidinylaminopyridazine und ihre verwendung als schnelldissoziierende antagonisten des dopamin-2-rezeptors

Info

Publication number
ATE486070T1
ATE486070T1 AT07847833T AT07847833T ATE486070T1 AT E486070 T1 ATE486070 T1 AT E486070T1 AT 07847833 T AT07847833 T AT 07847833T AT 07847833 T AT07847833 T AT 07847833T AT E486070 T1 ATE486070 T1 AT E486070T1
Authority
AT
Austria
Prior art keywords
piperidinylaminopyridazine
dopamine
antagonists
receptor
rapid dissociation
Prior art date
Application number
AT07847833T
Other languages
English (en)
Inventor
Gregor James Macdonald
Jose Ignacio Andres-Gil
Den Keybus Frans Alfons Maria Van
Jose Manuel Bartolome-Nebreda
Gool Michiel Luc Maria Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE486070(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE486070T1 publication Critical patent/ATE486070T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT07847833T 2006-12-08 2007-12-05 Piperidinylaminopyridazine und ihre verwendung als schnelldissoziierende antagonisten des dopamin-2-rezeptors ATE486070T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125685 2006-12-08
PCT/EP2007/063338 WO2008068277A1 (en) 2006-12-08 2007-12-05 Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists

Publications (1)

Publication Number Publication Date
ATE486070T1 true ATE486070T1 (de) 2010-11-15

Family

ID=37964744

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07847833T ATE486070T1 (de) 2006-12-08 2007-12-05 Piperidinylaminopyridazine und ihre verwendung als schnelldissoziierende antagonisten des dopamin-2-rezeptors

Country Status (28)

Country Link
US (1) US8466153B2 (de)
EP (1) EP2091938B1 (de)
JP (1) JP5255568B2 (de)
KR (1) KR101468384B1 (de)
CN (1) CN101547915B (de)
AR (1) AR064198A1 (de)
AT (1) ATE486070T1 (de)
AU (1) AU2007328897B2 (de)
BR (1) BRPI0720247A2 (de)
CA (1) CA2665924C (de)
CL (1) CL2007003556A1 (de)
CY (1) CY1112227T1 (de)
DE (1) DE602007010179D1 (de)
DK (1) DK2091938T3 (de)
EA (1) EA016654B1 (de)
ES (1) ES2354756T3 (de)
IL (1) IL199076A (de)
JO (1) JO2642B1 (de)
MX (1) MX2009005983A (de)
MY (1) MY148772A (de)
NO (1) NO20092574L (de)
NZ (1) NZ576484A (de)
PL (1) PL2091938T3 (de)
PT (1) PT2091938E (de)
SI (1) SI2091938T1 (de)
TW (1) TWI433676B (de)
UA (1) UA98940C2 (de)
WO (1) WO2008068277A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
WO2008128996A1 (en) * 2007-04-23 2008-10-30 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
KR20100016498A (ko) * 2007-04-23 2010-02-12 얀센 파마슈티카 엔.브이. 속해리성 도파민 2 수용체 길항제로서의 피리딘 유도체
JP5431305B2 (ja) * 2007-04-23 2014-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 高速解離性ドパミン２受容体アンタゴニストとしての４−アルコキシピリダジン誘導体
EP2310374B1 (de) * 2008-07-03 2012-10-31 Janssen Pharmaceutica N.V. Substituierte 6-(1-piperazinyl)pyridazine als antagonisten am 5-ht6-rezeptor
EP2307374B1 (de) * 2008-07-31 2017-01-25 Janssen Pharmaceutica NV Piperazin-1-yl-trifluoromethyl-substituierte-pyridine als schnell dissoziierende dopamin 2-rezeptorantagonisten
EP4574152A1 (de) * 2023-12-22 2025-06-25 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Kaliumkanalaktivatoren zur behandlung von epileptischen erkrankungen

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2341965C3 (de) * 1973-08-20 1979-01-25 C.H. Boehringer Sohn, 6507 Ingelheim 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen
NO147672C (no) 1975-09-23 1983-05-25 Janssen Pharmaceutica Nv Analogifremgangsmaate for fremstilling av n-aryl-n-(1-l1-4-piperidinyl)-arylacetamider
US4197304A (en) * 1975-09-23 1980-04-08 Janssen Pharmaceutica N.V. N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
EG12406A (en) * 1976-08-12 1979-03-31 Janssen Pharmaceutica Nv Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides
DE3218482A1 (de) 1982-05-15 1983-11-17 Bayer Ag, 5090 Leverkusen Substituierte 5-trifluormethyl-1,3,4-thiadiazol-2-yloxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
GB9216298D0 (en) 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
TW406075B (en) 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
US5753679A (en) 1995-05-10 1998-05-19 Hoffmann-La Roche Inc. Benzyl-piperidine derivatives
MY116093A (en) * 1996-02-26 2003-11-28 Upjohn Co Azolyl piperazinyl phenyl oxazolidinone antimicrobials
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
AU8457298A (en) * 1997-08-15 1999-03-08 Pfizer Products Inc. 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine D4 receptor
KR100261139B1 (ko) 1998-01-16 2000-08-01 황준수 신규한 알릴티오피리다진 유도체 및 그의 제조방법
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
WO2002068409A1 (en) 2001-02-23 2002-09-06 Merck & Co., Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
EP1443046B1 (de) 2001-10-09 2008-12-17 Kyorin Pharmaceutical Co., Ltd. Neue 4-(2-furoyl)-amino-piperidine, zwischenprodukte für deren synthese, verfahren zu deren herstellung und deren medizinische verwendung
AU2002360561A1 (en) 2001-12-11 2003-06-23 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
CA2474322A1 (en) 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
AU2003203148A1 (en) 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
EP1486490A1 (de) 2002-02-28 2004-12-15 Takeda Chemical Industries, Ltd. Azolverbindungen
SE0201544D0 (sv) 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
JP3625214B2 (ja) * 2002-09-26 2005-03-02 株式会社マンダム 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧料、医薬品及び食品
BRPI0410239A (pt) 2003-05-08 2006-05-16 Kyorin Seiyaku Kk composto de 4-(2-furoil)aminopiperidina e medicamento
WO2005005779A2 (en) 2003-07-14 2005-01-20 Genesis Mining Technologies (Pty) Ltd Dual retention cutting arrangement
CA2532236C (en) 2003-07-29 2011-08-23 Novo Nordisk A/S Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
JP2007501801A (ja) 2003-08-07 2007-02-01 日本たばこ産業株式会社 ピロロ［１，２−ｂ］ピリダジン誘導体
CA2563963A1 (en) 2004-04-28 2005-11-10 Pfizer Inc. 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
CA2568524A1 (en) 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
CA2585172C (en) 2004-10-29 2014-08-12 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of ppar
JP2008546784A (ja) 2005-06-20 2008-12-25 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なピペリジン誘導体
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
KR101117931B1 (ko) 2006-08-15 2012-04-12 에프. 호프만-라 로슈 아게 페닐, 피리딘 및 퀴놀린 유도체
CA2606658A1 (en) * 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
EP2307374B1 (de) 2008-07-31 2017-01-25 Janssen Pharmaceutica NV Piperazin-1-yl-trifluoromethyl-substituierte-pyridine als schnell dissoziierende dopamin 2-rezeptorantagonisten

Also Published As

Publication number Publication date
EA016654B1 (ru) 2012-06-29
DE602007010179D1 (de) 2010-12-09
AR064198A1 (es) 2009-03-18
PT2091938E (pt) 2011-01-20
IL199076A (en) 2012-12-31
WO2008068277A1 (en) 2008-06-12
SI2091938T1 (sl) 2011-02-28
US20100076187A1 (en) 2010-03-25
DK2091938T3 (da) 2011-02-07
CN101547915B (zh) 2013-08-21
BRPI0720247A2 (pt) 2013-12-31
CY1112227T1 (el) 2015-12-09
EA200970553A1 (ru) 2009-10-30
CL2007003556A1 (es) 2008-06-13
CA2665924C (en) 2014-08-12
TW200831098A (en) 2008-08-01
NZ576484A (en) 2010-10-29
CA2665924A1 (en) 2008-06-12
JP2010511673A (ja) 2010-04-15
HK1137434A1 (en) 2010-07-30
JO2642B1 (en) 2012-06-17
ES2354756T3 (es) 2011-03-17
AU2007328897B2 (en) 2013-01-10
US8466153B2 (en) 2013-06-18
MY148772A (en) 2013-05-31
KR101468384B1 (ko) 2014-12-03
CN101547915A (zh) 2009-09-30
UA98940C2 (ru) 2012-07-10
EP2091938B1 (de) 2010-10-27
AU2007328897A1 (en) 2008-06-12
JP5255568B2 (ja) 2013-08-07
EP2091938A1 (de) 2009-08-26
TWI433676B (zh) 2014-04-11
PL2091938T3 (pl) 2011-04-29
NO20092574L (no) 2009-09-08
MX2009005983A (es) 2009-06-16
KR20090089858A (ko) 2009-08-24

Similar Documents

Publication Publication Date Title
ATE370136T1 (de) Benzimidazolderivate und ihre verwendung als antagonisten des a ii rezeptors
ATE473214T1 (de) 2-(4-oxo-4h-chinazolin-3-yl)acetamide und ihre verwendung als vasopressin-v3-antagonisten
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
ATE542816T1 (de) Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors
EP2049110A4 (de) Verbrückte diazepanorexin-rezeptorantagonisten
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
ATE553084T1 (de) Polycyclische säureverbindungen als crth2- antagonisten und antiallergika
IL196181A0 (en) Substituted n-phenylmethyl-5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use
ATE478059T1 (de) Cinnamoylpiperazinderivate und ihre verwendung als par-1-antagonisten
DE602005023639D1 (de) Chinuclidinderivate und deren verwendung als muscarin-m3-rezeptor-antagonisten
IL187426A0 (en) Piperidin-4-yl-amide derivatives and their use as sst receptor subtype 5 antagonists
ATE454377T1 (de) 2-phenyl-6-aminocarbonylpyrimidinderivate und ihre verwendung als antagonisten am p2y12- rezeptor
DK2121630T3 (da) Hurtigt dissocierende dopamin-2-receptor-antagonister
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
ATE495167T1 (de) Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors
EP2146572A4 (de) Bicyclische heterocyclische anilid-cgrp-rezeptorantagonisten
EP2219660A4 (de) Modifizierte il-4-mutein-rezeptor-antagonisten
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
DE602007010179D1 (de) Piperidinylaminopyridazine und ihre verwendung als schnelldissoziierende antagonisten des dopamin-2-rezeptors
GB0611154D0 (en) Novel receptor antagonists and their methods of use
ATE469900T1 (de) Spiropiperidinderivate als antagonisten des via- rezeptors
EP1898905A4 (de) Hydroisoindolin-tachykinin-rezeptor-antagonisten
ATE500223T1 (de) Phenylpentadienoylderivate und ihre verwendung als par-1-antagonisten
ATE488519T1 (de) Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten
AP2009004734A0 (en) Substituted N-phenylmethyl-5-oxoproline-2-amides as P2X7-receptor antagonists and their methods of use

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2091938

Country of ref document: EP